These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2937403)

  • 1. Prolonged refractoriness to the diabetogenic action of streptozotocin in mice.
    Abramovici Y; Agarwal MK
    Biochem Med; 1985 Dec; 34(3):259-66. PubMed ID: 2937403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diabetogenic effects of streptozotocin in mice are prolonged and inversely related to age.
    Riley WJ; McConnell TJ; Maclaren NK; McLaughlin JV; Taylor G
    Diabetes; 1981 Sep; 30(9):718-23. PubMed ID: 6455320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of streptozotocin-induced insulitis and hyperglycaemia in the mouse.
    Sandler S; Andersson A
    Acta Pathol Microbiol Immunol Scand A; 1985 Mar; 93(2):93-8. PubMed ID: 3157292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KATP channel-deficient pancreatic beta-cells are streptozotocin resistant because of lower GLUT2 activity.
    Xu J; Zhang L; Chou A; Allaby T; Bélanger G; Radziuk J; Jasmin BJ; Miki T; Seino S; Renaud JM
    Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E326-35. PubMed ID: 18042662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of ALR/Lt islets to free radical-mediated diabetogenic stress is inherited as a dominant trait.
    Mathews CE; Leiter EH
    Diabetes; 1999 Nov; 48(11):2189-96. PubMed ID: 10535453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose streptozotocin induced diabetes in mice. Metabolic, light microscopical, histochemical, immunofluorescence microscopical, electron microscopical and morphometrical findings.
    Cossel L; Schneider E; Kuttler B; Schmidt S; Wohlrab F; Schade J; Bochmann C
    Exp Clin Endocrinol; 1985 Feb; 85(1):7-26. PubMed ID: 3157595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early manifestations in multiple-low-dose streptozotocin-induced diabetes in mice.
    Karabatas LM; Pastorale C; de Bruno LF; Maschi F; Pivetta OH; Lombardo YB; Chemes H; Basabe JC
    Pancreas; 2005 May; 30(4):318-24. PubMed ID: 15841040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin therapy prevents spontaneous recovery from streptozotocin-induced diabetes in Syrian hamsters. An autoradiographic and immunohistochemical study.
    Pour PM; Duckworth W; Carlson K; Kazakoff K
    Virchows Arch A Pathol Anat Histopathol; 1990; 417(4):333-41. PubMed ID: 2146799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of BB rat beta cells as determined by dose-responses to the cytotoxic effects of streptozotocin and alloxan.
    Yale JF; Grose M; Videtic GM; Marliss EB
    Diabetes Res; 1986 Mar; 3(3):161-7. PubMed ID: 2940045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very-low-dose streptozotocin induces diabetes in insulin promoter-mB7-1 transgenic mice.
    Harlan DM; Barnett MA; Abe R; Pechhold K; Patterson NB; Gray GS; June CH
    Diabetes; 1995 Jul; 44(7):816-23. PubMed ID: 7540575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal and comparative study of some structural and hormonal alterations in the endocrine pancreas of spontaneously diabetic and streptozotocin-induced diabetic mice.
    Stearns SB; Benzo CA
    Acta Anat (Basel); 1983; 115(3):193-203. PubMed ID: 6221500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single major gene controls most of the difference in susceptibility to streptozotocin-induced diabetes between C57BL/6J and C3H/HeJ mice.
    Kaku K; McGill J; Province M; Permutt MA
    Diabetologia; 1989 Oct; 32(10):716-23. PubMed ID: 2574118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A major loss in islet mass and B-cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin.
    Bonnevie-Nielsen V; Steffes MW; Lernmark A
    Diabetes; 1981 May; 30(5):424-9. PubMed ID: 6453032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of immunosuppression on streptozotocin-induced diabetes in C57BL/KsJ mice.
    Leiter EH; Beamer WG; Shultz LD
    Diabetes; 1983 Feb; 32(2):148-55. PubMed ID: 6219026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-cell apoptosis is responsible for the development of IDDM in the multiple low-dose streptozotocin model.
    O'Brien BA; Harmon BV; Cameron DP; Allan DJ
    J Pathol; 1996 Feb; 178(2):176-81. PubMed ID: 8683386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic control of susceptibility to streptozotocin diabetes in inbred mice: effect of testosterone and H-2 haplotype.
    Le PH; Leiter EH; Leyendecker JR
    Endocrinology; 1985 Jun; 116(6):2450-5. PubMed ID: 3888611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
    Kawai K; Suzuki S; Murayama Y; Watanabe Y; Yamashita K
    Diabetes Res Clin Pract; 1991 Jul; 12(3):163-72. PubMed ID: 1832376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice.
    Sestier C; Odent-Pogu S; Bonneville M; Maurel C; Lang F; Sai P
    Immunol Lett; 1985; 10(1):57-60. PubMed ID: 3159656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term diabetogenic effect of streptozotocin in rats.
    Ar'Rajab A; Ahrén B
    Pancreas; 1993 Jan; 8(1):50-7. PubMed ID: 8419909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early induction of diabetes in NOD mice by streptozotocin].
    Orlow S; Yasunami R; Boitard C; Bach JF
    C R Acad Sci III; 1987; 304(3):77-8. PubMed ID: 2949801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.